Global Influenza Treatment Market Worth USD 1.6 Billion With a CAGR of 4.2%

Introduction

The "anti-influenza drugs" refers to pharmaceuticals used to treat people with influenza. Types A, type, and type B influenza viruses are responsible for the viral infection known as influenza. The importance of influenza as a public health threat has led to the creation of new medications to lessen the disease's negative health and financial effects. The global market for influenza medicines is propelled by rising incidence and research funding for developing new medicines. The World Health Organization reports that 2018 influenza can cause mild to severe illness and even death, especially in high-risk patients. It is also estimated that between 290,000 and 650,000 lives will be lost annually due to this yearly increase (out of a total of 3 to 5 million cases of severe illness).

Market Dynamics

Growing Demand for Innovative and Efficient Medications Drives The Global Market

Since their introduction to the public, influenza treatments have undergone significant R&D developments. However, the U.S. Food and Drug Administration (FDA) has only approved four key medications for the treatment of influenza, despite the vast market expansion potential resulting from unmet patient requirements. There are only a handful of significant players in this industry, and the impact of comparably less expensive generics is increasing. However, some variants of the illness are resistant to treatment due to the cyclical nature of the influenza virus, and the increasing incidence of the disease further diminishes the likelihood of successful patient treatment. This has generated a substantial unmet treatment need in the market and is anticipated to be a significant factor driving market demand.

High Potential for Expansion in Emerging Markets Creates Tremendous Opportunities

Emerging markets offer influenza drug manufacturers attractive opportunities for business expansion. The dynamic life sciences industry drives market growth in countries such as China and India. In addition, the market expansion is due to an increase in awareness of the significant problems caused by influenza and an increase in knowledge of early influenza identification. In addition, advancements in the healthcare industries of developing nations are anticipated to contribute to market growth.

Regional Analysis

North America is the most significant global influenza treatment market shareholder and is estimated to exhibit a CAGR of 3.9% over the forecast period. An increase in prevalence causes a surge in demand for medications used to treat influenza in the area. Due to the region's rising frequency of influenza infection, North America held the greatest market share for influenza treatments and is predicted to keep doing so during the projected period. A major aspect that helps the market's expansion is the rise in knowledge surrounding the early identification of medical conditions for better treatment. The sharp increase in R&D spending for antiviral medications used to treat influenza is another significant factor fueling market expansion in the region. For instance, Pimodivir, a chemical developed by Johnson & Johnson (Janssen Pharmaceuticals) for the treatment of influenza, is currently in phase III of research.

Europe is expected to exhibit a CAGR of 5.6% over the forecast period. The rise in the number of people in Europe getting infected with the influenza virus is one factor contributing to the increase in the market for influenza treatment in Europe. Anti-viral medications, which are essential in the treatment of the underlying medical condition, have become more necessary due to this sharp rise in incidence. These anti-viral pharmaceuticals are essential in the care of the underlying medical condition. The presence of the great majority of notable competitors in the region, which results in medicines being widely accessible, is another element that contributes to the expansion of the industry. An increase in the amount of money spent on healthcare is another aspect that contributes to the expansion of the industry.

Key Highlights

• The global influenza treatment market size was valued at USD 1.07 billion in 2022. It is estimated to reach USD 1.6 billion by 2031, growing at a CAGR of 4.2% during the forecast period (2023–2031).
• Based on the product, the global influenza treatment Market is bifurcated into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil,and others. The Oseltamivir Phosphate segment dominates the global market and is projected to exhibit a CAGR of 3.91% over the forecast period.
• Based on distribution channels, the global influenza treatment market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacy segment owns the highest market share and is predicted to exhibit a CAGR of 3.6% during the forecast period.
• North America is the most significant global influenza treatment market shareholder and is estimated to exhibit a CAGR of 3.9% over the forecast period.

Competitive Players

1. Roche Holding AG
2. GlaxoSmithKline plc
3. AstraZeneca plc
4. Sanofi S.A.
5. Seqirus (a subsidiary of CSL Limited)
6. Johnson & Johnson
7. Pfizer Inc.
8. Novartis International AG
9. Daiichi Sankyo Company, Limited
10. Mylan N.V.

Recent Developments

• July 2022-Seqirus and a business of CSL Limited partnered for multi-year influenza medication research with the University of Liverpool Pandemic Institute. Seqirus would participate in research projects, inform the generation of the threat of seasonal influenza, and develop innovative approaches to the pandemic response.

Segmentation

1. By Product
   1. Peramivir
   2. Zanamivir
   3. Oseltamivir Phosphate
   4. Baloxavir Marboxil
   5. Other
2. By Distribution Channel
   1. Retail Pharmacy
   2. Hospital Pharmacy
   3. Others